Search Icon
Home
Resources
Reports

Reports

  • Reports

White Paper: Access Denied: Why New Generics Are Not Reaching America’s Seniors
  • Reports

The Unintended Economics of the BLOCKING Act
  • Reports

Medicare Part D Generic Drug Tiering Request for Comment: Implications for Patient Out-of-Pocket Spending and Part D Plan Costs
  • Reports

7 Policy Solutions
  • Reports

Report: 2019 Generic Drug & Biosimilars Access & Savings in the U.S.
  • Reports

2020 Generic Drug & Biosimilars Access and Savings in the U.S. Report
  • Reports

The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It
  • Reports

Biosimilars Handbook
  • Reports

Commitment to Quality Excellence
  • Reports

White Paper (Part 1) Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America’s Patients
  • Reports

2018 Generic Drug Access and Savings Report
  • Reports

Bates-White Report: CPI-Based Medicaid Rebates Harm Generic Competition
Load More
Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington DC 20001
JOIN

Advocacy

About Us

Events

Resources

Sign-up for Update

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Subscribe
© 2025 Association for Accessible Medicines (AAM), All Rights Reserved Privacy Policy  |  Terms of Use  |  Contact

Stay Connected

For the latest updates, follow us on social media.

Facebook-f X-twitter Linkedin-in Youtube Instagram